Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration

Página do item simplificado
dc.contributor.authorAvila, M. P.
dc.contributor.authorFarah, M. E. [UNIFESP]
dc.contributor.authorSantos, A.
dc.contributor.authorDuprat, J. P. [UNIFESP]
dc.contributor.authorWoodward, B. W.
dc.contributor.authorNau, J.
dc.contributor.institutionUniversidade Federal de Goiás (UFG)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionCtr Med Puerta Hierro
dc.contributor.institutionNeoVista
dc.date.accessioned2016-01-24T13:52:21Z
dc.date.available2016-01-24T13:52:21Z
dc.date.issued2009-03-01
dc.description.abstractBackground/aims: This study evaluated the short-term safety and feasibility of epiretinal strontium-90 brachytherapy delivered concomitantly with intravitreal bevacizumab for the treatment of subfoveal CNV due to AMD for 12 months. A 3-year follow-up is planned.Methods: in this prospective, non-randomised, multicentre study, 34 treatment-naive patients with predominantly classic, minimally classic and occult subfoveal CNV lesions received a single treatment with 24 Gy beta radiation (strontium-90) and two injections of the anti-VEGF antibody bevacizumab. Adverse events were observed. BCVA was measured using standard ETDRS vision charts.Results: Twelve months after treatment, no radiation-associated adverse events were observed. in the intent-to-treat (ITT) population, 91% of patients lost <3 lines (15 ETDRS letters) of vision at 12 months, 68% improved or maintained their BCVA at 12 months, and 38% gained >= 3 lines. the mean change in BCVA observed at month 12 was a gain of 8.9 letters.Conclusion: the safety and efficacy of intraocular, epiretinal brachytherapy delivered concomitantly with anti-VEGF therapy for the treatment of subfoveal CNV secondary to AMD were promising in this small study population. Long-term safety will be assessed for 3 years. This regimen is being evaluated in a large, multicentre, phase III study.en
dc.description.affiliationUniv Fed Goias, Ctr Referencia Oftalmol, Goiania, Go, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Oftalmol, São Paulo, Brazil
dc.description.affiliationCtr Med Puerta Hierro, Ctr Retina Med & Quirurg SC, Guadalajara, Jalisco, Mexico
dc.description.affiliationNeoVista, Fremont, CA USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Oftalmol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent305-309
dc.identifierhttp://dx.doi.org/10.1136/bjo.2008.145912
dc.identifier.citationBritish Journal of Ophthalmology. London: B M J Publishing Group, v. 93, n. 3, p. 305-309, 2009.
dc.identifier.doi10.1136/bjo.2008.145912
dc.identifier.issn0007-1161
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/31376
dc.identifier.wosWOS:000263655800009
dc.language.isoeng
dc.publisherB M J Publishing Group
dc.relation.ispartofBritish Journal of Ophthalmology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.titleTwelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degenerationen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral